SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________ FORM 6-K Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 March 11, 2003 SYNSORB Biotech Inc. Commission File No. 0-29214 (Translation of registrant’s name into English) 411 – 19th Street SE Calgary, Alberta, Canada, T2E 6J7 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Washington, D.C. 20549

FORM 6-K

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

January 7, 2003

SYNSORB Biotech Inc.

Commission File No. 0-29214

(Translation of registrant's name into English)

411 – 19th Street SE

Calgary, Alberta, Canada, T2E 6J7

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Act of 1934.

Yes

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule
12g3-2(b): 82- N/A

Exhibit Number ~~Exhibit 1. Press~~ ~~release of SYNSORB Biotech Inc. dated January 6, 2003~~ Exhibit

~~SIGNATURES~~1. Press release of SYNSORB Biotech Inc. dated March 11, 2003

~~Pursuant~~2. toManagement ~~the~~Discussion ~~requirements~~and ~~of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.~~Analysis

~~SYNSORB~~3. ~~Biotech~~Annual ~~Inc.~~Financial Statements for the year ended December 31, 2002

~~Dated: January~~4. 7,Notice ~~2003~~of Meeting and Information Circular

~~By:~~5. Form of Proxy

~~(Signed) “Jim~~SIGNATURES ~~Silye”~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

~~Jim~~Dated: ~~Silye~~March 11, 2003 SYNSORB BIOTECH INC. By: (Signed) “Bruce Kenway” Bruce Kenway Director

~~President~~Exhibit ~~& CEO~~ Index

Exhibit Number

Exhibit

Page

Press release of SYNSORB Biotech Inc. dated March 11, 2003

Management Discussion and Analysis

Annual Financial Statements for the year ended December 31, 2002

Notice of Meeting and Information Circular

Form of Proxy

Filing Compare · HAWKER RESOURCES INC